SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
21
02
2023
accepted:
13
09
2023
revised:
07
09
2023
medline:
17
12
2023
pubmed:
28
10
2023
entrez:
27
10
2023
Statut:
ppublish
Résumé
KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute leukemia which mostly affects children. Transcriptomics-based characterization and chemical interrogation identified kinases as key drivers of survival and drug resistance in KMT2A-R leukemia. In contrast, the contribution and regulation of phosphatases is unknown. In this study we uncover the essential role and underlying mechanisms of SET, the endogenous inhibitor of Ser/Thr phosphatase PP2A, in KMT2A-R-leukemia. Investigation of SET expression in acute myeloid leukemia (AML) samples demonstrated that SET is overexpressed, and elevated expression of SET is correlated with poor prognosis and with the expression of MEIS and HOXA genes in AML patients. Silencing SET specifically abolished the clonogenic ability of KMT2A-R leukemic cells and the transcription of KMT2A targets genes HOXA9 and HOXA10. Subsequent mechanistic investigations showed that SET interacts with both KMT2A wild type and fusion proteins, and it is recruited to the HOXA10 promoter. Pharmacological inhibition of SET by FTY720 disrupted SET-PP2A interaction leading to cell cycle arrest and increased sensitivity to chemotherapy in KMT2A-R-leukemic models. Phospho-proteomic analyses revealed that FTY720 reduced the activity of kinases regulated by PP2A, including ERK1, GSK3β, AURB and PLK1 and led to suppression of MYC, supporting the hypothesis of a feedback loop among PP2A, AURB, PLK1, MYC, and SET. Our findings illustrate that SET is a novel player in KMT2A-R leukemia and they provide evidence that SET antagonism could serve as a novel strategy to treat this aggressive leukemia.
Identifiants
pubmed: 37891368
doi: 10.1038/s41388-023-02840-1
pii: 10.1038/s41388-023-02840-1
pmc: PMC10709139
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
Myeloid-Lymphoid Leukemia Protein
149025-06-9
Protein Phosphatase 2
EC 3.1.3.16
SET protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3670-3683Subventions
Organisme : Cancer Research UK
ID : 20784
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Front Oncol. 2015 Feb 16;5:21
pubmed: 25763353
Nat Med. 2015 Dec;21(12):1481-90
pubmed: 26594843
Leukemia. 2023 May;37(5):988-1005
pubmed: 37019990
Oncogene. 2022 Jun;41(24):3328-3340
pubmed: 35525905
Cell. 2021 Jun 10;184(12):3143-3162.e32
pubmed: 34004147
Oncotarget. 2015 Feb 28;6(6):4299-314
pubmed: 25726524
Life Sci Alliance. 2023 Mar 1;6(5):
pubmed: 36858798
Leukemia. 2017 Jan;31(1):40-50
pubmed: 27443263
Genes Cells. 2021 Oct;26(10):830-837
pubmed: 34320268
JAMA. 2010 Dec 22;304(24):2706-15
pubmed: 21177505
Leukemia. 2014 Sep;28(9):1915-8
pubmed: 24781014
Mol Cancer Res. 2014 Jun;12(6):924-39
pubmed: 24667985
Blood. 2011 Oct 13;118(15):4150-8
pubmed: 21844565
Cancer Cell. 2020 Feb 10;37(2):200-215.e5
pubmed: 32049046
Mol Cancer. 2014 Feb 20;13:32
pubmed: 24555657
Blood. 2015 Jun 11;125(24):3747-55
pubmed: 25931585
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62
pubmed: 24927563
Cancer Cell. 2011 Jul 12;20(1):66-78
pubmed: 21741597
Mol Cell Biol. 2004 Jan;24(2):617-28
pubmed: 14701735
Signal Transduct Target Ther. 2023 Feb 27;8(1):80
pubmed: 36843114
Leukemia. 2018 Apr;32(4):882-889
pubmed: 29089643
Blood. 2008 Nov 15;112(10):4193-201
pubmed: 18716133
Cancer Res. 2010 Jul 1;70(13):5438-47
pubmed: 20551067
Biochim Biophys Acta Gene Regul Mech. 2020 Sep;1863(9):194584
pubmed: 32534041
Nature. 2011 Oct 02;478(7370):529-33
pubmed: 21964340
Leukemia. 2011 Apr;25(4):606-14
pubmed: 21233840
J Biol Chem. 2020 Mar 27;295(13):4194-4211
pubmed: 32071079
Front Pharmacol. 2021 Sep 14;12:741413
pubmed: 34594227
Oncogene. 2011 Jun 2;30(22):2504-13
pubmed: 21297667
Front Cell Dev Biol. 2019 May 15;7:81
pubmed: 31157223
Cancer Res. 2016 Mar 1;76(5):1158-69
pubmed: 26627013
Clin Transl Med. 2022 Jun;12(6):e933
pubmed: 35730653
Genes Chromosomes Cancer. 1992 Oct;5(3):227-34
pubmed: 1384675
PLoS One. 2014 Jul 22;9(7):e103033
pubmed: 25050888
Biosci Rep. 2022 Nov 30;42(11):
pubmed: 36345878
J Clin Invest. 2013 Oct;123(10):4144-57
pubmed: 23999433
Nat Biotechnol. 2020 Apr;38(4):493-502
pubmed: 31959955
Nat Genet. 2015 Sep;47(9):1030-7
pubmed: 26237430
Elife. 2021 Jul 26;10:
pubmed: 34310280
Blood Cancer J. 2020 Jan 8;10(1):3
pubmed: 31913266
Sci Signal. 2013 Mar 26;6(268):rs6
pubmed: 23532336
Oncogenesis. 2014 Jun 16;3:e106
pubmed: 24932908
Cancer Lett. 2020 Jan 1;468:1-13
pubmed: 31593801
Cell Oncol (Dordr). 2019 Dec;42(6):829-845
pubmed: 31493143
Autophagy. 2011 Jul;7(7):707-15
pubmed: 21460633
Lancet Oncol. 2013 May;14(6):e229-38
pubmed: 23639323
Leukemia. 2014 Mar;28(3):589-99
pubmed: 24240200
Haematologica. 2012 Apr;97(4):543-50
pubmed: 22133779
J Biol Chem. 1997 Nov 7;272(45):28407-14
pubmed: 9353299
Oncotarget. 2016 Apr 26;7(17):23106-27
pubmed: 27036015
Cell Stem Cell. 2009 Feb 6;4(2):129-40
pubmed: 19200802
Tumori. 2012 Mar-Apr;98(2):252-6
pubmed: 22677993
Nat Cell Biol. 2004 Apr;6(4):308-18
pubmed: 15048125
Cell Death Dis. 2019 Nov 7;10(11):847
pubmed: 31699964
Hemasphere. 2019 Jun 04;3(3):e195
pubmed: 31723831
FASEB J. 2019 Jun;33(6):7647-7666
pubmed: 30917007
Nature. 2006 Aug 17;442(7104):818-22
pubmed: 16862118
Neurobiol Aging. 2013 Jul;34(7):1748-58
pubmed: 23374587
FEBS Lett. 2005 Jan 31;579(3):757-62
pubmed: 15670842
Int J Mol Sci. 2021 Apr 28;22(9):
pubmed: 33924850
Int J Mol Sci. 2021 Nov 26;22(23):
pubmed: 34884632
Nature. 2020 Jan;577(7789):266-270
pubmed: 31827282
Mol Cell. 2016 Nov 3;64(3):493-506
pubmed: 27773673
Cancer Cell. 2005 Nov;8(5):355-68
pubmed: 16286244
Blood. 2009 Mar 12;113(11):2375-85
pubmed: 19056693
Blood. 2008 May 1;111(9):4668-80
pubmed: 18299449
Cancers (Basel). 2023 Mar 27;15(7):
pubmed: 37046649
Leukemia. 2017 Mar;31(3):669-677
pubmed: 27573555
J Clin Invest. 2018 Dec 3;128(12):5517-5530
pubmed: 30260324
Mol Cancer Ther. 2014 Apr;13(4):938-47
pubmed: 24448818
Leukemia. 2022 Jun;36(6):1541-1549
pubmed: 35368048
Front Pediatr. 2017 Feb 09;5:4
pubmed: 28232907
J Clin Invest. 2007 Sep;117(9):2408-21
pubmed: 17717597
Oncotarget. 2016 Jun 6;8(33):53989-54003
pubmed: 28903318